|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pfizer Inc. (PFE) Spinoff No Need for Worry in Groton, Conn.: Analyst
1/16/2013 8:27:59 AM
A news report Tuesday that Pfizer Inc. could be split into two companies in the next few years shouldn’t necessarily concern scientists at the company’s laboratories in Groton, according to a health care firm analyst. Les Funtleyder, president of the investment advisory division of New York-based Poliwogg Inc., said a report by Bloomberg news service that sparked speculation Pfizer might soon cut itself in two is largely conjecture. New York-based Pfizer still has to finalize its already announced animal-health spinoff and other issues before tackling a possible move to split its new-medicines operations from its generics portfolio, a process that would take well over a year, he said. But Funtleyder said any spinoff that eventually occurs would likely be a good thing for Pfizer’s R&D scientists. Pfizer employs about 3,500 people in the region. "It probably wouldn’t mean a change as far as employment," Funtleyder said. "It could mean more focus on R&D." Bloomberg reported Tuesday that Geno Germano, Pfizer’s president of specialty care and oncology, said in an interview that the company’s four business divisions would probably be whittled down to two at some point, representing so-called "innovative business" (R&D for new products) and "value business" (generics). "We really see the business segmenting into these two segments with pretty different capabilities, and we would want to organize in a way that we realize the most value for shareholders," Germano told Bloomberg. Germano didn’t specifically say Pfizer was preparing to spin off one of its core businesses, but analysts already had been speculating that a split might be in the cards, and Germano’s comments fueled further speculation.
|
|
|
|
|
|
|
|
|
|
|